Skip to content

Study · Randomized controlled trial · n = 24 · 2014

5 results

Switching brain serotonin with oxytocin.

Mottolese R, Redouté J, Costes N, Le Bars D, Sirigu A

Proceedings of the National Academy of Sciences of the United States of America27 May 2014Cited by 137 (Europe PMC)

PMID24912179 (opens in a new tab)PMCIDPMC4060712 (opens in a new tab)DOI10.1073/pnas.1319810111 (opens in a new tab)PepBankPUB-24912179
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy subjects, oxytocin increased [18F]MPPF binding potential, a marker of the 5-HT1A system, in the dorsal raphe nucleus.

    In plain wordsIn healthy people, oxytocin changed a brain scan marker of the serotonin system in the dorsal raphe nucleus, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Increase5-HT1A binding potential in the dorsal raphe nucleus
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DRN), the core area of 5-HT synthesis, and in the amygdala/hippocampal complex, insula, and orbitofrontal cortex.
    1 context sentence
    Summary · context
    We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.
  2. 02HumanRandomized controlled trialMechanism

    In healthy subjects, oxytocin increased [18F]MPPF binding potential in the amygdala/hippocampal complex.

    In plain wordsIn healthy people, oxytocin changed a brain scan marker of the serotonin system in the amygdala and hippocampus, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Increase5-HT1A binding potential in the amygdala/hippocampal complex
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DRN), the core area of 5-HT synthesis, and in the amygdala/hippocampal complex, insula, and orbitofrontal cortex.
    1 context sentence
    Summary · context
    We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.
  3. 03HumanRandomized controlled trialMechanism

    In healthy subjects, oxytocin increased [18F]MPPF binding potential in the insula.

    In plain wordsIn healthy people, oxytocin changed a brain scan marker of the serotonin system in the insula, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Increase5-HT1A binding potential in the insula
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DRN), the core area of 5-HT synthesis, and in the amygdala/hippocampal complex, insula, and orbitofrontal cortex.
    1 context sentence
    Summary · context
    We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.
  4. 04HumanRandomized controlled trialMechanism

    In healthy subjects, oxytocin increased [18F]MPPF binding potential in the orbitofrontal cortex.

    In plain wordsIn healthy people, oxytocin changed a brain scan marker of the serotonin system in the orbitofrontal cortex, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Increase5-HT1A binding potential in the orbitofrontal cortex
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    OXT increased [(18)F]MPPF nondisplaceable binding potential (BPND) in the dorsal raphe nucleus (DRN), the core area of 5-HT synthesis, and in the amygdala/hippocampal complex, insula, and orbitofrontal cortex.
    1 context sentence
    Summary · context
    We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.
  5. 05HumanRandomized controlled trialMechanism

    In healthy subjects, oxytocin-induced changes in [18F]MPPF binding in the dorsal raphe correlated with changes in the right amygdala, which correlated with changes in hippocampus, insula, subgenual and orbitofrontal cortex.

    In plain wordsIn healthy people, oxytocin-linked changes in a serotonin scan marker were correlated across a circuit of linked brain regions.

    Peptide
    Oxytocin
    Outcome
    Not applicableCorrelation of oxytocin-induced binding changes between brain regions
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, the amygdala appears central in the regulation of 5-HT by OXT: [(18)F]MPPF BPND changes in the DRN correlated with changes in right amygdala, which were in turn correlated with changes in hippocampus, insula, subgenual, and orbitofrontal cortex, a circuit implicated in the control of st…
    1 context sentence
    Summary · context
    We asked whether these chemical messengers interact in the regulation of emotion-based behavior by administering OXT or placebo to 24 healthy subjects and mapping cerebral 5-HT system by using 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.